Market Closed -
Nasdaq
04:00:00 2024-07-12 pm EDT
|
5-day change
|
1st Jan Change
|
45.88
USD
|
+3.36%
|
|
+7.57%
|
+106.02%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,265
|
3,001
|
1,785
|
1,543
|
1,245
|
2,605
|
-
|
-
|
Enterprise Value (EV)
1 |
3,184
|
2,690
|
1,582
|
1,421
|
1,215
|
2,528
|
2,589
|
2,379
|
P/E ratio
|
-6.96
x
|
-9.14
x
|
1.24
x
|
-6.64
x
|
-3.52
x
|
43.3
x
|
-8.16
x
|
-10.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
27.7
x
|
14.8
x
|
-
|
108
x
|
46.4
x
|
61.4
x
|
20.8
x
|
11.8
x
|
EV / Revenue
|
27
x
|
13.2
x
|
-
|
99.8
x
|
45.3
x
|
59.6
x
|
20.7
x
|
10.8
x
|
EV / EBITDA
|
-7.61
x
|
-8.79
x
|
-4.29
x
|
-3.73
x
|
-3.16
x
|
-6.45
x
|
-6.68
x
|
-7.82
x
|
EV / FCF
|
-8.32
x
|
-8.8
x
|
-3.83
x
|
-4.52
x
|
-4.09
x
|
-8.35
x
|
-11.5
x
|
-9.85
x
|
FCF Yield
|
-12%
|
-11.4%
|
-26.1%
|
-22.1%
|
-24.5%
|
-12%
|
-8.68%
|
-10.2%
|
Price to Book
|
4.47
x
|
7.48
x
|
1.54
x
|
1.4
x
|
1.53
x
|
1.6
x
|
1.94
x
|
2.15
x
|
Nbr of stocks (in thousands)
|
68,371
|
69,260
|
54,308
|
54,945
|
55,891
|
56,773
|
-
|
-
|
Reference price
2 |
47.75
|
43.33
|
32.87
|
28.08
|
22.27
|
45.88
|
45.88
|
45.88
|
Announcement Date
|
2/13/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
117.9
|
203.2
|
-
|
14.24
|
26.82
|
42.39
|
124.9
|
221
|
EBITDA
1 |
-418.2
|
-306.2
|
-369.2
|
-380.5
|
-384.9
|
-391.7
|
-387.8
|
-304.2
|
EBIT
1 |
-426.3
|
-316.1
|
-378.4
|
-389
|
-391.5
|
-394.8
|
-364.8
|
-294.6
|
Operating Margin
|
-361.57%
|
-155.59%
|
-
|
-2,732.07%
|
-1,459.52%
|
-931.34%
|
-292.02%
|
-133.33%
|
Earnings before Tax (EBT)
1 |
-411.5
|
-327.4
|
-356.5
|
-231.8
|
-352.1
|
-284.5
|
-313.8
|
-233
|
Net income
1 |
-411.5
|
-327.4
|
1,605
|
-231.8
|
-352.1
|
70.87
|
-342.1
|
-286.2
|
Net margin
|
-348.97%
|
-161.11%
|
-
|
-1,627.82%
|
-1,312.63%
|
167.19%
|
-273.82%
|
-129.5%
|
EPS
2 |
-6.860
|
-4.740
|
26.55
|
-4.230
|
-6.330
|
1.060
|
-5.621
|
-4.502
|
Free Cash Flow
1 |
-382.8
|
-305.7
|
-413.1
|
-314.4
|
-297.1
|
-302.7
|
-224.7
|
-241.5
|
FCF margin
|
-324.64%
|
-150.43%
|
-
|
-2,207.58%
|
-1,107.49%
|
-714.02%
|
-179.84%
|
-109.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
0.832
|
5.582
|
3.516
|
4.31
|
5.609
|
6.712
|
7.399
|
7.103
|
8.189
|
9.746
|
11.41
|
12.55
|
26.84
|
39.4
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-88.82
|
-91.89
|
-
|
-104.9
|
-90.72
|
-95
|
-98
|
-100
|
-
|
-
|
EBIT
1 |
-104.8
|
-101.1
|
-97.64
|
-91.09
|
-99.17
|
-90.61
|
-93.7
|
-100.9
|
-106.3
|
-92.07
|
-98.6
|
-100.2
|
-104
|
-94.35
|
-73.98
|
Operating Margin
|
-
|
-12,156.85%
|
-1,749.19%
|
-2,590.73%
|
-2,300.97%
|
-1,615.49%
|
-1,396.01%
|
-1,363.66%
|
-1,496.23%
|
-1,124.34%
|
-1,011.76%
|
-878.23%
|
-828.4%
|
-351.53%
|
-187.76%
|
Earnings before Tax (EBT)
1 |
-98.58
|
-94.77
|
-91.81
|
-81.75
|
36.53
|
-81.02
|
-83.81
|
-91.32
|
-95.94
|
-81.55
|
-89.3
|
-51.33
|
161.9
|
-67.09
|
-65.1
|
Net income
1 |
-94.63
|
-94.77
|
-91.81
|
-81.75
|
36.53
|
-81.02
|
-83.81
|
-91.32
|
-95.94
|
-81.55
|
-92.16
|
92.81
|
84.1
|
-67.09
|
-65.1
|
Net margin
|
-
|
-11,391.11%
|
-1,644.68%
|
-2,325%
|
847.47%
|
-1,444.43%
|
-1,248.6%
|
-1,234.27%
|
-1,350.7%
|
-995.84%
|
-945.68%
|
813.64%
|
670.11%
|
-249.97%
|
-165.21%
|
EPS
2 |
-1.740
|
-1.740
|
-1.680
|
-1.490
|
0.6700
|
-1.470
|
-1.510
|
-1.640
|
-1.720
|
-1.450
|
-1.591
|
3.193
|
1.108
|
-1.405
|
-1.120
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/15/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
80.9
|
311
|
203
|
122
|
30.1
|
76.8
|
15.4
|
226
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-383
|
-306
|
-413
|
-314
|
-297
|
-303
|
-225
|
-242
|
ROE (net income / shareholders' equity)
|
-62%
|
-63%
|
190%
|
-19.4%
|
-36.8%
|
0.34%
|
-21.2%
|
-12.6%
|
ROA (Net income/ Total Assets)
|
-47%
|
-37.5%
|
140%
|
-17.3%
|
-32.4%
|
56.3%
|
-19.4%
|
-11.4%
|
Assets
1 |
874.6
|
871.8
|
1,145
|
1,338
|
1,088
|
125.9
|
1,763
|
2,506
|
Book Value Per Share
2 |
10.70
|
5.790
|
21.40
|
20.10
|
14.60
|
28.70
|
23.70
|
21.30
|
Cash Flow per Share
2 |
-
|
-
|
-6.740
|
-5.650
|
-5.320
|
-4.620
|
-4.510
|
-
|
Capex
1 |
12.2
|
14.9
|
5.74
|
4.88
|
1
|
5.5
|
8
|
20
|
Capex / Sales
|
10.32%
|
7.34%
|
-
|
34.28%
|
3.72%
|
12.98%
|
6.4%
|
9.05%
|
Announcement Date
|
2/13/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
45.88
USD Average target price
52.83
USD Spread / Average Target +15.16% Consensus |
1st Jan change
|
Capi.
|
---|
| +106.02% | 2.6B | | +20.12% | 126B | | +25.25% | 119B | | +25.56% | 27.95B | | -19.51% | 20.5B | | -14.36% | 17.12B | | -15.63% | 16.1B | | -46.67% | 14.97B | | +11.89% | 14.84B | | +57.74% | 14.38B |
Bio Therapeutic Drugs
|